IMMUNE
LL-37
Subcutaneous injection
Overview
The only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from the precursor protein hCAP18. LL-37 disrupts microbial membranes through electrostatic interactions and exerts broad-spectrum activity against bacteria, fungi, and enveloped viruses.
Mechanism of Action
Beyond direct antimicrobial effects, it modulates innate immunity by recruiting immune cells, promoting angiogenesis, and regulating inflammatory cytokine release.
​Research Summary & Key Findings
Demonstrated broad-spectrum antimicrobial activity against antibiotic-resistant organisms including MRSA. Plays a role in wound healing and immune defense at epithelial surfaces. Dysregulation implicated in rosacea (overexpression) and chronic wounds (deficiency). Research suggests therapeutic potential in chronic infections and wound healing.
Clinical Status
FDA APPROVED
LL-37 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
Subcutaneous injection (weekly)
Oral (daily - Rybelsus)
References
PRIMARY LITERATURE
PRIMARY LITERATUREPeer-reviewed literature indexed by the National Library of Medicine.
Registered interventional and observational studies, including status and phase.
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Administration Routes
METABOLIC
Semaglutide (Ozempic/Wegovy)
METABOLIC
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
METABOLIC
Tirzepatide (Mounjaro/Zepbound)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
METABOLIC
AOD-9604
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.